Skip to main content

Table 1 Schedule of enrollment, assessments, and data collection for the period of the trial

From: Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

  Study period
Time points Enrolment Allocation Post allocation (months)
  -t0 t0 6 12 18 24 30 36
Eligibility screen X        
Informed consent X        
Allocation   X       
Conventional screening
Semi-annual ultrasound and alpha-fetoprotein for all people with cirrhosis hepatitis B virus infection with any degree of fibrosis     X   X   X
Digital rectal examination and anal cytology to all MSM every 1–3 years     X   X   X
Cervical cytology every 1–3 years to all sexually active women, at least 25 to 64 years old     X   X   X
Mammogram every 1–3 years to women between 50 and 70 years     X   X   X
Rectal digital exam ± PSA every 1–3 years for all men> 50 years     X   X   X
Fecal occult blood test every 1–3 years in people between 50 and 75 years     X   X   X
Enhanced screening
Over 40 years of age, active smokers or who would have abandoned in the last 3 years, with an accumulated index ≥ 20 pack-years and without contraindications for thoracic surgery, and without recent lung infections in the last 2 months     X   X   X
Semi-annual ultrasound and alpha-fetoprotein for all people with chronic liver disease with fibrosis ≥ F3 of any cause (including HCV infection) or any fibrosis for hepatitis B virus    X X X X X X
Digital examination and semi-annual anal cytology MSM    X X X X X X
Semiannual cervical cytology to all sexually active women between the ages of 21 and 64, including cotest (cervical cytology and HPV test) from the age of 30 if available (in that case, controls will be made annually)    X X X X X X
Annual mammogram for women between 50 and 70 years     X   X   X
PSA and annual digital rectal exam to all men ≥ 50 years     X   X   X
Annual fecal occult blood to people >  40 years     X   X   X
Annual general inspection for skin lesions suggestive of malignancy     X   X   X